AN2 Therapeutics receives IND approval from the US FDA to proceed with the planned global phase 2 study of oral afterborol in polycythemia vera -. Company announcement - FT.com.
🇺🇸 USA · Map
AN2 Therapeutics receives IND approval from the US FDA to proceed with the planned global phase 2 study of oral afterborol in polycythemia vera -. Company announcement - FT.com.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in